According to a statement today, January 16, ace investor Ashish Kachoria has invested Rs 160 crore in CURO Biosciences Private Limited, the parent company of ErlySign.
“This funding will help us complete clinical trials, secure CDSCO approval, and bring ErlySign’s oral cancer detection kit to market. It will also support research and development, team expansion, and further patent filings.” said the company.
ErlySign was founded by Shubhendra Singh and Deovrat Begde with a vision to make early detection of cancer painless, easy and affordable for everyone. This is India’s first salivary biomarker-based test that can identify pre-cancerous conditions long before visible symptoms appear, revolutionizing preventive healthcare and early diagnosis.
Also read: ParkMate receives $1.2 million in funding led by growth-stage venture fund Cactus Partners
Commenting on the funding, Mr. Singh said, “Our initial studies revealed exceptional results, achieving 100% specificity and 98.04% sensitivity. This product is now available for multiple HCG It is in the final stages of clinical trials at our facility and is expected to be a game changer, going beyond early detection and serving as an important screening tool to eliminate unnecessary biopsies and invasive procedures. .”
ErlySign’s innovation is a biomarker-based test kit that can detect oral pre-cancerous conditions in just 15 minutes using a simple, non-invasive saliva sample. This innovative solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming, and expensive. ErlySign’s test kit promises to be a painless, affordable, and immediate alternative for early cancer detection, offering the promise of timely intervention and improved survival rates.
Also read: Foxtale raises $30 million from Japan’s KOSE and more
